MedPath

Effect of prebiotic and probiotic mixture in the treatment of pediatric non-alcoholic fatty liver disease (NAFLD)

Not Applicable
Completed
Conditions
Obese children with NAFLD
Registration Number
TCTR20170128001
Lead Sponsor
The Ratchadaphiseksomphot Fund, Faculty of Medicine, Chulalongkorn University
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
40
Inclusion Criteria

Obese children with NAFLD, age 6 to 18 years
- Obese is defined by weight more than 2SD in the same gender
and same age.
- NAFLD is defined by the presence of steatosis with controlled attenuation parameter (CAP) values ≥250 dB/m from Fibroscan with CAP.

Exclusion Criteria

1.Fatty liver from metabolic liver disease, viral hepatitis, Wilson disease, autoimmune hepatitis
2.History of hepatotoxic drug or substance used
3.Allergic or serious ADR to probiotics and prebiotics
4.Poor compliance

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Hepatic fat content 16 weeks controlled attenuation parameter (CAP) by fibroscan
Secondary Outcome Measures
NameTimeMethod
iver fibrosis 16 weeks Liver stiffness measurement (LSM) by fibroscan,Body mass index Z-score 16 weeks 2007 WHO child growth references
© Copyright 2025. All Rights Reserved by MedPath